Abstract Erratic, "unscheduled", vaginal bleeding continues to be the greatest disadvantage associated with widespread use of long-acting, progestogen-only methods of contraception. As a consequence, it is also the main reason for premature discontinuation of use of these methods in most cultures. From other perspectives, these methods have high acceptability, very high contraceptive efficacy and a range of valuable, added, non-contraceptive health benefits. There has been widespread awareness of the variability of these vaginal bleeding patterns associated with long-acting methods for several decades and much research has been invested into studying their patterns and implications. Considerable research has also been directed towards trying to understand the underlying mechanisms responsible for the unpredictable bleeding. Much has been clarified about the multiple mechanisms contributing to the appearance of superficial, thin-walled fragile vessels within the endometrium of many of those women with troublesome bleeding, but there is still little understanding of why some women develop these vessels and others have no fragile vessels (and may therefore develop amenorrhea). We now have several medical approaches to reliably stopping a prolonged episode of troublesome bleeding, but no good therapy to produce long-lasting relief from recurrence of erratic bleeding in predisposed women. Future understanding of the variability in individual endometrial responses in different women may be a key to solving this frustrating symptom.
Introduction
Abnormal uterine bleeding is a significant social, financial and practical problem for women. In addition, since abnormal bleeding may indicate pathology of the genital tract, women may be advised to undergo invasive and expensive investigations which generate cost and anxiety, and which rarely indicate pathology in younger women. The great majority of premenopausal women experience regular uterine bleeding [1] . During the early post-menarchal years and during the menopause transition, irregular bleeding is more common and may reflect anovulatory cycles [2] .
Exogenous sex steroids given for contraception, treatment of menstrual disturbances or hormone replacement therapy are commonly associated with unscheduled uterine bleeding. This review will address the classification, patterns of bleeding, mechanisms and management of iatrogenic unscheduled bleeding, principally bleeding associated with steroid contraceptives, and will focus especially on recent developments. Unscheduled bleeding on HRT will not be addressed.
Current issues
The term "breakthrough bleeding" refers to unscheduled endometrial bleeding in sex steroid users. This has been a significant clinical problem since the introduction of hormonal contraception. The World Health Organization and United States National Institutes of Health have conducted five individual or joint workshops addressing the mechanisms and management of unscheduled bleeding since 1979 [3] [4] [5] [6] [7] . The outcome from these multidisciplinary meetings has been a greatly improved understanding of the epidemiology, patient impact and mechanisms underlying unscheduled bleeding, but these have not yet lead to effective, novel prevention or treatment strategies. The last of these joint meetings was held in 2006 [7] , and a moderate amount of new information has been published since.
Medical interventions or devices can cause or exacerbate abnormal uterine bleeding via several mechanisms. Interventions include medicated or inert intrauterine devices and pharmacological agents that affect the endometrium, alter coagulation mechanisms or interfere with regular ovulation [8] .
Systemic synthetic sex steroids (estrogens, progestogens and androgens) given alone or in combination commonly impact on ovarian sex steroid production via central or direct ovarian actions and may also directly affect the endometrium. The most common clinical indication for sex steroids is for contraception. These include combined oral contraceptives containing estrogen and progestogen, transdermal and vaginal combined preparations, progestogenonly contraceptives which may be oral, subdermal, injectable or intrauterine, anti-progestogens or selective progesterone receptor modulators.
All of these preparations can also be used for therapy, or even prevention, of many common gynaecological symptoms. Similar issues of unscheduled endometrial bleeding can occur when these preparations are used for such therapeutic purposes. Premature discontinuation of hormonal therapy because of nuisance-value, unscheduled bleeding, may lead to greater resort by physicians to otherwise unnecessary surgery for these symptoms.
Normal endometrial bleeding occurs following progestogen withdrawal from an estrogen-primed endometrium [9] . Unscheduled bleeding may occur in users of exogenous sex steroids (usually hormonal contraceptives), in women using hormonal therapies for menstrual disorders or menopausal symptoms or in those taking non-hormonal preparations that interfere with normal ovulation.
Defining and classifying iatrogenic endometrial bleeding
Progress in understanding the mechanisms and optimal management of unscheduled endometrial bleeding has been limited by a lack of standardized terminology for unscheduled bleeding and an absence of standardized methodology for investigating and classifying bleeding patterns [8] . This issue has recently been resolved through an international collaborative working party (The FIGO Menstrual Disorders Working Group) which has developed a system ("The FIGO Classification of causes of abnormal uterine bleeding in non-gravid women in the reproductive years") using nine basic categories arranged according to the acronym "PALM-COEIN" The components of the "PALM" group are definable "structural" entities that can be measured using imaging with or without histopathological changes (Polyp, Adenomyosis, Leiomyoma, Malignancy and Hyperplasia. The COEIN group are non-structural changes, which are not identifiable by imaging or histopathology: Coagulopathy, Ovulatory Disorders, Endometrium, Iatrogenic and Not Yet Classified [8] . These non-structural changes are all a presumed function of varying disturbances of specific groups of molecular pathways at a local level within the reproductive tract or the controlling centers in the brain and anterior pituitary gland, or in the circulating coagulation system.
Uterine bleeding is almost inevitably modified in some way by progestogen and /or estrogen therapies, with patterns ranging from frequent and prolonged bleeding, spotting or amenorrhea. Occasionally, the bleeding is "chaotic", and for individual women there are no established ways of predicting what kind of bleeding patterns a product may induce in that particular woman. The least predictable patterns are associated with long-acting progestogen-only contraceptives. New analysis systems and terminologies have been devised to define normal and abnormal patterns [10] , although the principles of assessment of these specific hormonal contraceptive-induced patterns were first established more than 40 years ago [11] [12] [13] . The erratic nature and sometimes prolonged bleeding, and bleeding-free, intervals led to a need to use a longer timeline than the typical "month" to describe bleeding patterns, and a "reference period" of 90 days has become the standard for longacting progestogen contraceptives where bleeding patterns may be erratic or infrequent. Clinically important bleeding patterns have been defined to describe regularity and heaviness (see Table 1 ).
Unscheduled bleeding with hormonal contraceptives
Combined estrogen and progestogen methods are usually given cyclically and aim to induce regular endometrial withdrawal bleeds. Progestogen-only methods, including orals, are usually given continuously, aiming to avoid regular bleeds and to induce amenorrhea (such as depot medroxyprogesterone acetate [DMPA; Depo-Provera] or the etonogestrel-releasing subdermal implant; [Implanon]). For Table 1 Clinically significant bleeding patterns, as determined by detailed WHO review [14] No bleeding: No days of bleeding/spotting entered throughout the reference period Prolonged bleeding: ≥10 days in one episode Frequent bleeding: >4 episodes in one 90-day reference period Infrequent bleeding: <2 episodes in one 90-day reference period Irregular bleeding: A range of varying lengths of bleeding-free intervals >17 days within one 90-day reference period continuous progestogen methods, any bleeding can be considered as unscheduled [8] .
The clinical consequences of unscheduled bleeding will vary between women and may be influenced by the level of pretreatment counseling and patient factors such as educational level and cultural beliefs [15] . It is important that physicians and health workers are aware of the serious impact which this unscheduled bleeding can have on continuation of method usage. It has been recognised for several decades that this unpredictable bleeding is the major cause of premature discontinuation of all of the progestogen-only and long-acting methods. Unscheduled bleeding or spotting (very light bleeding, not usually requiring formal sanitary protection) may be less acceptable to women who are unable to participate in certain religious or social practices and sexual activity during "menstruation", such as some Muslim women, and to those with a low tolerance of menstrual disruption, such as adolescents [16] . It is of interest that some religious leaders have recently announced that unscheduled bleeding with hormonal contraception is not "menstruation", and therefore should not interfere with observance of religious practices. The general pattern of bleeding is light, infrequent and sometimes prolonged, and even frequent or prolonged episodes do not commonly lead to iron deficiency anaemia [17] .
Clinicians should consider the possibility that unscheduled bleeding, especially a change in bleeding patterns, represents cervico-vaginal infection in high-risk populations and investigate and treat this accordingly.
Unscheduled bleeding with combined contraceptives
Unscheduled vaginal bleeding affects around 25 % of COCP users during the initial 3 months of use, but declines in incidence with ongoing use. Unscheduled bleeding is more common with lower dose (20 μg) compared to standard (30 or 35 μg) of ethinyl estradiol (EE) preparations [18] . Unscheduled bleeding varies between different combined hormonal contraceptives, but is not significantly reduced by continuous regimens compared to cyclic regimens, or, initially, by the newer estradiol-17β (E 2 )-based COCPs [19] . This contrasts strongly with the recent recognition that the E2-based combinations produce a remarkably effective therapeutic reduction in menstrual blood loss in heavy menstrual bleeders, close to that of the levonorgestrelreleasing intrauterine system [20] . This reduction is probably much greater than other COCPs and is not a general COCP class-effect.
Combined contraceptives generally rely on daily or weekly use, so are more commonly associated with compliance and behavioral issues compared to long-acting methods. Missed pills or incorrect use of a combined vaginal ring may lead to increased pituitary production of FSH, follicular stimulation and endogenous sex steroid secretion. Consequently, endometrial stimulation from endogenous sex steroids may alter bleeding patterns and lead to breakthrough bleeding. The presence of large ovarian follicles on ultrasound in oral contraceptive users is predictive of breakthrough bleeding [21] Rates of unscheduled (breakthrough) bleeding and spotting are lower with the contraceptive vaginal ring than with COCP [22] .
Unscheduled bleeding with progestogen-only contraceptives
Depending on the method, progestogen-only contraceptives may aim to provide regular uterine bleeding patterns (the original norethisterone and levonorgestrel-releasing progestogen-only pills) or amenorrhea (all other progestogenonly contraceptives). Progestogenic contraceptives have the advantage of offering long-term contraception, which improves efficacy and is highly acceptable to many women. Unscheduled bleeding is the main disadvantage of progestogen-only contraceptives and occurs to a varying degree and with different characteristics in all of these methods. Interpreting signs and symptoms of unplanned pregnancy, whether intrauterine or extrauterine, can be challenging. Pregnancy testing is appropriate for progestogen-only oral contraceptive users experiencing nausea, breast tenderness, a change in bleeding pattern or lower abdominal pain.
Mechanisms of unscheduled bleeding with progestogen-only contraceptives
Progestogen exposure affects all cellular elements of the endometrium and it is likely that unscheduled bleeding arises due to changes in the tightly regulated system of vascular, stromal and epithelial interaction seen during the normal menstrual cycle. The exact mechanisms of progestogen-induced breakthrough bleeding are not fully understood, but superficial vascular fragility is a key feature [23] . In addition, local changes in endometrial steroid response, structural integrity, tissue perfusion and changes in local angiogenesis all contribute to unscheduled bleeding (see Table 2 ).
In order for vaginal bleeding to occur, endometrial blood vessels and their overlying epithelium must both, simultaneously, break down [25] . Long-acting progestogen exposure alters endometrial vascular development leading to irregularly distributed, superficial enlarged and fragile capillaries and venules embedded in a collapsed stromal extracellular matrix [26] . These vessels bleed easily on minimal pressures, and show evidence of disturbed angiogenesis with immature basement membrane development and altered expression of tissue angiogenic factors [27] . It appears that abnormal and unrestrained angiogenesis leads to fragile leaky blood vessels that lead to light but prolonged and frequent bleeding, characteristic of unscheduled bleeding with long-acting progestogen contraceptives [23] .
The local factors leading to abnormal angiogenesis are not known, but may arise due to changes in endometrial blood flow leading to impaired perfusion of microvascular beds and hypoxia/reperfusion injury [28] . Use of longacting progestogen contraceptives leads to increased local expression of reactive oxygen species and the synthesis of angiogenic factors such as vascular endothelial growth factor (VEGF) and angiopoeitin-2 [29] . Over-expression of VEGF will lead to the breakdown of endothelial junctions and increased vascular fragility. Loss of stromal integrity due to breakdown of the perivascular extracellular matrix and increased activity of proteolytic factors such as certain matrix metalloproteinases (MMP) will further reduce vascular integrity [30] . See Table 3 . Progestogen exposure also alters endometrial sex steroid receptor expression. This varies between contraceptive methods, but there is a general trend towards down-regulation of estrogen and progesterone receptors within the glandular and stromal cells [24] . Tissue repair and remodeling is a crucial process for endometrial Menstrual changes occur in almost all women using DMPA and are the most frequent cause for discontinuation of these and all other progestogen-only contraceptives [32] . Proactive patient education before initiation of DMPA, as well as supportive follow-up, can improve tolerance of menstrual changes. During the first months of use, episodes of unpredictable bleeding and spotting lasting seven days or longer are common. Bleeding decreases with use and at one year 50 % of women experience amenorrhea; this increases to 75 % with long-term use [33] . Similar bleeding patterns are reported with the new subcutanous preparation [34] . Many women may view amenorrhea (along with a reduction or elimination of menstrual cramps and other cyclical symptoms) as one of the advantages of using this method.
Abnormal bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS)
As with DMPA and other progestogen-only contraceptives, unpredictable uterine bleeding is the most common reason for discontinuation of the LNG-IUS [32] . Unscheduled bleeding is most common during the early months of LNG-IUS use and tends to resolve with time. By 12 months up to 50 % of women have amenorrhea or infrequent bleeding [35] . Addressing patient preferences and assessing acceptance of menstrual disturbances are integral to efforts aimed at reducing early discontinuation rates. Adequate and specific counseling about likely changes in bleeding patterns before placement is essential to increase patient acceptability. By contrast with the tendency to frequent, prolonged, very light bleeding or spotting in the early months after LNG-IUS insertion, the total amount of blood which LNG-IUS users lose is dramatically decreased-by around 90 % compared with normal menstruation. Recent data confirm that the LNG-IUS is an excellent therapy for women with most of the major causes for heavy menstrual bleeding [36] . These experiences and impacts of different types of bleeding indicate that a number of different cellular and molecular mechanisms are probably at play within the endometrium of LNG-IUS users at different times and in different women. Use of the LNG-IUS is known to induce endometrial changes which may contribute to breakthrough bleeding. These changes include down regulation of both ER and PR expression, with an increase in PRA related to PRB, an increase in large thin-walled vessels on the endometrial surface, an increase in vascular endothelial growth factor levels in the endometrium and a local increase in tissue factor [37] . However, the exact mechanism by which these changes induce abnormal bleeding is not fully understood. Similar changes in endometrial conditions are probably also at play in other progestogen-only method users, but are not so obvious as in the LNG-IUS users.
Abnormal bleeding with subdermal contraceptive implants
Subdermal contraceptive implants are one of the most effective reversible contraceptive methods with a failure rate of only 0.01 per 100 etonogestrel implants fitted [16] . Bleeding problems are the most common reason for women to request premature removal of contraceptive implants. Around one quarter of those who report 50-90 days bleeding or spotting in the first reference period will request early implant removal [9] . Recently, combined data from eleven clinical trials showed that the most common bleeding patterns with Implanon were amenorrhea (22.2 %), infrequent bleeding (33.6 %), frequent bleeding (6.7 %), and frequent and/or prolonged bleeding (17.7 %) [17] . The number of bleeding days was generally not increased but the pattern was unpredictable. Of clinical relevance is that bleeding patterns experienced during the initial three months may predict future patterns for the majority of women. The group of women with favorable bleeding patterns during the first three months tended to continue with this pattern throughout the first two years of use. It is encouraging that the group with unfavorable initial patterns had at least a 50 % chance that the pattern would improve. Around 11.3 % of users discontinued owing to bleeding irregularities, mainly because of prolonged flow and frequent, irregular bleeding. Most women (77 %) who had baseline dysmenorrhea experienced complete resolution of symptoms. Effective preinsertion counseling on the possible changes in bleeding patterns may improve continuation rates [17] .
Management of unscheduled bleeding with progestogen-only contraception
Unscheduled bleeding is one of the main drawbacks of progestogen-only contraception. Mifepristone and other progesterone antagonists or receptor modulators may be effective treatments for abnormal bleeding with these methods. Mifepristone (150 mg once-a-month) reduced unscheduled bleeding in users of the progestogen-only pill containing desogestrel [38] . Mifepristone 50 mg once-amonth reduced the duration of bleeding in Norplant users [39] . In new users of DMPA, 50 mg of mifepristone once every two weeks reduced unscheduled bleeding [40] , and low dose mifepristone in combination with ethinyl estradiol or doxycline was effective in stopping a bleeding episode in Implanon users [41] . The action of mifepristone in improving bleeding patterns is not fully understood, but is likely to be endometrial rather than through an effect on ovarian function or ovulation in these contraceptive users [39] . Some studies have shown that estrogen supplements (eg, 1.25 mg of oral conjugated estrogen, 1 to 2 mg of oral micronized E 2 or 100 μg E 2 patches) may terminate a current bleeding episode with DMPA [32] but do not improve long-term bleeding patterns.
COCP containing higher dose estrogen (50 μg of EE/ 250 μg LNG for 20 days) will effectively stop a bleeding episode with contraceptive implants, but may cause nausea [42] . Lower dose COCP may shorten bleeding episodes but do not decrease their frequency [43] . Clinical options to treat problematic bleeding in progestogen contraceptive users are currently limited and there are no studies supporting a long-term beneficial effect of any therapeutic regimen. A recent systematic review concluded that there is a lack of high quality data to support routine clinical use of any interventions to treat persistent unscheduled bleeding with progestogen-only contraceptives [43] . However, there are pragmatic measures which may assist some individuals with troublesome unscheduled bleeding [16] . Figure 1. 
New directions for therapy
Future studies aimed at understanding the disturbed endometrial mechanisms in women with the most troublesome frequent and prolonged bleeding are needed to increase the acceptability of progestogen-only methods [16] . Agents that promote endometrial repair by increasing blood vessel and epithelial integrity offer the greatest promise. Amenorrhea is the most achievable clinical target in the majority of those using progestogen-only methods, and current, continuing barriers to acceptability of amenorrhea in women of different ages and varied cultural backgrounds also require greater understanding of local cultural issues. The pursuit of predictable amenorrhea also requires considerably more scientific study to understand and achieve such highly predictable levels. Fig. 1 The management of unacceptable bleeding patterns in etonogestrel-releasing subdermal contraceptive implants (Implanon/Nexplanon) [16] Progesterone receptor modulators are being developed for contraceptive application and show short-term efficacy for the management of unscheduled bleeding with the LNG-IUS [44] . Endometrial bleeding has a significant inflammatory component and anti-inflammatory agents such as celecoxib or naproxen may be effective for short-term inhibition of bleeding. These would be costeffective for women in resource-poor countries [45] . Prevention, rather than therapy, of unscheduled bleeding is a more attractive proposition and once-a-month administration of agents such as mifepristone may be effective in preventing unscheduled bleeding [43] .
10 Iatrogenic unscheduled bleeding due to non-hormonal agents Systemic agents that interfere with dopamine metabolism may cause abnormal bleeding secondary to disrupted ovulation. Such bleeding disturbances usually occur with irregular and usually infrequent bleeding patterns. Tricyclic antidepressants and phenothiazines are commonly used in reproductive-aged women and may impact dopamine metabolism by recbpducing serotonin uptake. The mechanism of abnormal bleeding is thought to be via prolactin secretion, again inhibiting ovulation and may occur with any agent that impacts on serotonin uptake. Abnormal bleeding may also occur in users of anticoagulant agents such as warfarin and heparin. This is thought to be due to impaired hemostasis within the vascular lumen [8] .
Conclusion
Unscheduled bleeding is common in women using hormonal contraception of all kinds, but particularly in those using progestogen-only methods. In those with new onset unscheduled bleeding, consider investigation for infection and pregnancy in those at risk. A pelvic examination is required in women using hormonal contraception if there are risk factors for an STI, if there are concurrent symptoms or if she requires a Pap smear according to national/professional guidelines (www.fsrh.org). There are currently no established therapies for unscheduled bleeding with hormonal contraception, but the methods indicated above may be useful to provide temporary relief and facilitate method continuation following discussion with the patient. There is no evidence that these supplemental hormonal therapies interfere with contraceptive efficacy [46] . Realistic pre-treatment counseling about likely bleeding patterns is good practice and may substantially improve acceptability and continuation with progestogen-only methods [47] .
The endometrium is a very unforgiving tissue when attempts are made to manipulate reproductive events and expose it to unfamiliar patterns of reproductive steroids. Decades of searching for a 'simple and reversible' endometrial treatment which reliably produces amenorrhea have allowed some tantalizing advances, but there is still some way to go. There is a real need to study that subgroup of women with the most troublesome bleeding patterns in a more focused manner, probably concentrating on several, linked endometrial molecular pathways, concentrating initially on mechanisms of angiogenesis. We do not yet understand what processes lead to the development of fragile surface vessels which seem to be one of the keys to unscheduled bleeding. Many of these women with 'bad' bleeding patterns can be identified in the early stages of subdermal etonogestrel implant use, so that recruitment should not be too difficult. These women will need to be compared with those who achieve predictable amenorrhea. Better understanding of this group of mechanisms should allow exploration of innovative technologies and specific treatments. Our optimism of three decades ago [3] may have been somewhat misplaced, but many women of the modern world do achieve close to predictable amenorrhea. We need to understand the others.
